Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

New data shows no increased cardiovascular risk of the osteoporosis drug vs anabolic agents — and even suggests a lower risk.

As the age-old proverb rightly states, "You are what you eat." A balanced diet lays the foundation for healthy living and ...

UK Biobank completes the world’s largest medical imaging project with 100,000 volunteers scanned, offering scientists ...